Position in NVO
as of Jun 30, 2026
· filed Jul 10, 2026
Position Value
$873,706
+$194,750 QoQ
Shares Held
18,225
-1.4% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.60%
of 13F equity value
Holder Rank
#557
of 1,348 holders
Holding Since
Mar 2020
6 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in NVO Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Investors Research Corp holds $5,482,615 across 10 Drug Manufacturers - General names. NVO ranks #3 (15.9% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | MRK |
Merck & Co., Inc.
|
8,779 | $1,128,101 | |
| 2 | PFE |
Pfizer Inc
|
38,962 | $938,204 | |
| 3 | NVO |
Novo Nordisk A S
This page
|
18,225 | $873,706 | |
| 4 | GSK |
GSK plc
|
14,952 | $783,783 | |
| 5 | SNY |
Sanofi
|
16,468 | $702,524 | |
| 6 | BMY |
Bristol Myers Squibb Co
|
8,628 | $497,145 | |
| 7 | BIIB |
Biogen Inc.
|
1,641 | $354,554 | |
| 8 | AZN |
Astrazeneca PLC
|
642 | $121,736 |
All Filings in NVO
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $873,706 | 18,225 | Shares | Sole | 2026-07-10 | |
| 2026-03-31 | $678,956 | 18,475 | Shares | Sole | 2026-04-03 | |
| 2022-12-31 | $4,330 | 32 | Shares | Sole | 2023-02-06 | |
| 2022-09-30 | $6,575 | 66 | Shares | Sole | 2022-11-10 | |
| 2022-06-30 | $3,788 | 34 | Shares | Sole | 2022-07-21 | |
| 2020-03-31 | $513,506 | 8,530 | Shares | Sole | 2020-05-05 | |
| No filing history on record for this holder in this stock. | ||||||